Published on
January 25, 2021
- 13:00 GMT
Albireo Announces U.S. FDA Acceptance of New Drug Application for Odevixibat
- Company receives FDA Priority Review with PDUFA date set for July 20, 2021 - - Submission data for PFIC types 1, 2, 3, supporting once-daily use across a wide range of patients - - FDA has granted odevixibat Fast Track, Rare Pediatric Disease and Orphan …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
